Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer
NCT00006370
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
275
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Lung Cancer
Interventions
RADIATION:
yttrium Y 90-edotreotide
Sponsor
Novartis Pharmaceuticals